meso-6k_20210406.htm

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 Form 6-K

Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934

For the month of April 2021

Commission File Number 001-37626

Mesoblast Limited

(Exact name of Registrant as specified in its charter)

Not Applicable

(Translation of Registrant’s name into English)

Australia
(
Jurisdiction of incorporation or organization)

 

Silviu Itescu

Chief Executive Officer and Executive Director

Level 38

55 Collins Street

Melbourne 3000

Australia

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F:

Form 20-F Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Yes No

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Yes No

 


INFORMATION CONTAINED ON THIS REPORT ON FORM 6-K

On April 6, 2021, Mesoblast Limited submitted an Initial Director’s Interest Notice Form to the Australian Securities Exchange, a copy of which is attached to this report as Exhibit 99.1.

 



SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly organized.

 

 

 

 

 

 

 

 

Mesoblast Limited

 

 

 

 

 

 

/s/ Niva Sivakumar

 

 

 

 

 

 

 

 

 

Niva Sivakumar

 

 

 

 

Company Secretary

 

 

 

Dated: April 8, 2021


 

INDEX TO EXHIBITS

 

 

 

Item

 

 

 

 

 

99.1

 

Initial Director’s Interest Notice, Philip Facchina.

 

 

 

 

 

 

 

 

 

meso-ex991_6.htm

Appendix 3X               Exhibit 99.1

Initial Director’s Interest Notice

 

 

Rule 3.19A.1

Appendix 3X

 

Initial Director’s Interest Notice

 

Information or documents not available now must be given to ASX as soon as available.  Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/9/2001.

Name of entity

MESOBLAST LIMITED

ABN

68 109 431 870

 

We (the entity) give ASX the following information under listing rule 3.19A.1 and as agent for the director for the purposes of section 205G of the Corporations Act.  

 

Name of Director

Philip Facchina

Date of appointment

29 March 2021

 

Part 1 - Director’s relevant interests in securities of which the director is the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

 

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

 

 

Number & class of securities

 

Nil

 

 

 

 

 

 

 

 

 

 

 

 

 


 

+ See chapter 19 for defined terms.

 

11/3/2002

Appendix 3X  Page 1


Appendix 3X

Initial Director’s Interest Notice

 

 

Part 2 – Director’s relevant interests in securities of which the director is not the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

 

Name of holder & nature of interest

Note: Provide details of the circumstances giving rise to the relevant interest.

 

HNP, LLC (Philip Facchina, is a member of HNP, LLC and is deemed to be the beneficial owner of these securities)

 

 

 

 

 

 

 

Number & class of Securities

 

273,224 Ordinary shares

68,306 Warrants

 

 

Part 3 – Director’s interests in contracts

 

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

 

Detail of contract

N/A

Nature of interest

 

 

N/A

Name of registered holder

(if issued securities)

 

N/A

No. and class of securities to which interest relates

 

 

N/A

 

 

+ See chapter 19 for defined terms.

 

Appendix 3X Page 2

11/3/2002